Ribonuclease 7 Shields the Kidney and Bladder from Invasive Uropathogenic


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
08 2019
Historique:
received: 14 09 2018
accepted: 17 04 2019
pubmed: 27 6 2019
medline: 28 4 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

Evidence suggests that antimicrobial peptides, components of the innate immune response, protect the kidneys and bladder from bacterial challenge. We previously identified ribonuclease 7 (RNase 7) as a human antimicrobial peptide that has bactericidal activity against uropathogenic To investigate RNase 7's role in preventing urinary tract infection (UTI), we quantified urinary RNase 7 concentrations in 29 girls and adolescents with a UTI history and 29 healthy female human controls. To assess RNase 7's antimicrobial activity Compared with controls, study participants with a UTI history had 1.5-fold lower urinary RNase 7 concentrations. When RNase 7 was silenced These findings provide evidence that RNase 7 has a role in kidney and bladder host defense against UPEC and establish a foundation for investigating RNase 7 as a UTI prognostic marker or nonantibiotic-based therapy.

Sections du résumé

BACKGROUND
Evidence suggests that antimicrobial peptides, components of the innate immune response, protect the kidneys and bladder from bacterial challenge. We previously identified ribonuclease 7 (RNase 7) as a human antimicrobial peptide that has bactericidal activity against uropathogenic
METHODS
To investigate RNase 7's role in preventing urinary tract infection (UTI), we quantified urinary RNase 7 concentrations in 29 girls and adolescents with a UTI history and 29 healthy female human controls. To assess RNase 7's antimicrobial activity
RESULTS
Compared with controls, study participants with a UTI history had 1.5-fold lower urinary RNase 7 concentrations. When RNase 7 was silenced
CONCLUSIONS
These findings provide evidence that RNase 7 has a role in kidney and bladder host defense against UPEC and establish a foundation for investigating RNase 7 as a UTI prognostic marker or nonantibiotic-based therapy.

Identifiants

pubmed: 31239387
pii: ASN.2018090929
doi: 10.1681/ASN.2018090929
pmc: PMC6683711
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimicrobial Cationic Peptides 0
Ribonucleases EC 3.1.-
Ribonuclease 7 EC 3.1.27.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1385-1397

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK109242
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114035
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK118306
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK102594
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115737
Pays : United States

Informations de copyright

Copyright © 2019 by the American Society of Nephrology.

Références

EMBO J. 2000 Jun 15;19(12):2803-12
pubmed: 10856226
Environ Health Perspect. 2001 Aug;109(8):801-8
pubmed: 11564615
Infect Immun. 2002 Jun;70(6):3053-60
pubmed: 12010997
J Biol Chem. 2002 Nov 29;277(48):46779-84
pubmed: 12244054
Nature. 2003 Apr 3;422(6931):522-6
pubmed: 12660734
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1333-8
pubmed: 14739341
Kidney Int. 2004 Mar;65(3):791-7
pubmed: 14871399
Genomics. 2005 Feb;85(2):208-20
pubmed: 15676279
J Immunol Methods. 2005 Jan;296(1-2):115-23
pubmed: 15680156
Nat Med. 2006 Jun;12(6):636-41
pubmed: 16751768
Mol Divers. 2006 Nov;10(4):585-97
pubmed: 16969722
J Immunol. 2006 Oct 1;177(7):4773-84
pubmed: 16982918
J Immunol. 2007 Apr 15;178(8):4832-45
pubmed: 17404264
Mol Biosyst. 2007 May;3(5):317-35
pubmed: 17460791
Cell Microbiol. 2007 Sep;9(9):2230-41
pubmed: 17490405
J Am Soc Nephrol. 2007 Nov;18(11):2810-6
pubmed: 17942949
J Am Soc Nephrol. 2008 Dec;19(12):2364-74
pubmed: 18753256
Eur J Clin Invest. 2008 Oct;38 Suppl 2:21-8
pubmed: 18826478
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14966-71
pubmed: 19706440
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22439-44
pubmed: 20018753
FEBS J. 2010 Apr;277(7):1713-25
pubmed: 20180804
BMC Cancer. 2010 Apr 14;10:142
pubmed: 20398276
Nat Rev Urol. 2010 Dec;7(12):653-60
pubmed: 21139641
Kidney Int. 2011 Jul;80(2):174-80
pubmed: 21525852
Vital Health Stat 13. 2011 Apr;(169):1-38
pubmed: 21614897
Pediatrics. 2011 Sep;128(3):595-610
pubmed: 21873693
Kidney Int. 2013 Apr;83(4):615-25
pubmed: 23302724
Dis Model Mech. 2013 Jul;6(4):934-41
pubmed: 23519031
Nat Rev Immunol. 2013 Nov;13(11):790-801
pubmed: 24096337
PLoS One. 2013 Oct 21;8(10):e77714
pubmed: 24204930
J Clin Invest. 2014 Jul;124(7):2963-76
pubmed: 24937428
Kidney Int. 2015 Jan;87(1):151-61
pubmed: 25075772
J Immunol. 2014 Dec 15;193(12):6081-9
pubmed: 25398327
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Crit Rev Microbiol. 2016 Sep;42(5):780-99
pubmed: 26006172
Pediatrics. 2015 Jul;136(1):e13-21
pubmed: 26055855
Nat Rev Nephrol. 2015 Nov;11(11):642-55
pubmed: 26149835
J Am Soc Nephrol. 2016 Mar;27(3):835-46
pubmed: 26293821
J Am Soc Nephrol. 2016 Jun;27(6):1625-34
pubmed: 26449605
PLoS One. 2015 Dec 10;10(12):e0144024
pubmed: 26658437
Int J Mol Sci. 2016 Mar 22;17(3):423
pubmed: 27011175
Kidney Int. 2016 Sep;90(3):568-79
pubmed: 27401534
Open Forum Infect Dis. 2017 Feb 24;4(1):ofw281
pubmed: 28480273
J Clin Invest. 2018 Dec 3;128(12):5634-5646
pubmed: 30418175
Infect Drug Resist. 2018 Nov 15;11:2321-2333
pubmed: 30532565
Methods Enzymol. 1994;236:405-20
pubmed: 7968625
Cancer Res. 1998 Jan 1;58(1):14-9
pubmed: 9426049
Infect Immun. 1998 Jun;66(6):2798-802
pubmed: 9596750

Auteurs

Tad Eichler (T)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.

Kristin Bender (K)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.

Matthew J Murtha (MJ)

Centers for Clinical and Translational Research and.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and.

Laura Schwartz (L)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.

Jackie Metheny (J)

Centers for Clinical and Translational Research and.

Lindsey Solden (L)

Microbial Pathogenesis, The Research Institute at Nationwide Children's, Columbus, Ohio.

Robert M Jaggers (RM)

Microbial Pathogenesis, The Research Institute at Nationwide Children's, Columbus, Ohio.

Michael T Bailey (MT)

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and.
Microbial Pathogenesis, The Research Institute at Nationwide Children's, Columbus, Ohio.

Sudipti Gupta (S)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.

Claudia Mosquera (C)

Centers for Clinical and Translational Research and.

Christina Ching (C)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and.
Divisions of Urology and.
Departments of Pediatric Surgery and.

Krista La Perle (K)

Comparative Pathology and Mouse Phenotyping Shared Resource, The Ohio State University College of Veterinary Medicine, Columbus, Ohio.

Birong Li (B)

Centers for Clinical and Translational Research and.

Brian Becknell (B)

Centers for Clinical and Translational Research and.
Nephrology and Urology Research Affinity Group.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and.
Nephrology, and.
Pediatrics, Nationwide Children's, Columbus, Ohio.

John David Spencer (JD)

Centers for Clinical and Translational Research and John.Spencer@nationwidechildrens.org.
Nephrology and Urology Research Affinity Group.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and.
Nephrology, and.
Pediatrics, Nationwide Children's, Columbus, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH